Pub Date : 2024-01-01Epub Date: 2023-11-03DOI: 10.1097/ICU.0000000000001014
Dante Buonsanti, Miguel Raimundo, Oliver Findl
Purpose of review: To showcase the majority of online intraocular lens (IOL) calculation tools and highlight some of their characteristics.
Recent findings: Online tools are available for preoperative and postoperative IOL-related calculations, including IOL power and toricity selection for standard patients, patients who underwent prior refractive surgery, keratoconus, limbal relaxing incisions for astigmatism management, realignment of a misplaced or rotated toric IOL, surgical induced astigmatism (SIA), formulae comparison, and other tools.
Summary: As there are new online developments and technology is advancing rapidly, we hope that this review will assist ophthalmologists in becoming acquainted with a large variety of online tools.
{"title":"Online intraocular lens calculation.","authors":"Dante Buonsanti, Miguel Raimundo, Oliver Findl","doi":"10.1097/ICU.0000000000001014","DOIUrl":"10.1097/ICU.0000000000001014","url":null,"abstract":"<p><strong>Purpose of review: </strong>To showcase the majority of online intraocular lens (IOL) calculation tools and highlight some of their characteristics.</p><p><strong>Recent findings: </strong>Online tools are available for preoperative and postoperative IOL-related calculations, including IOL power and toricity selection for standard patients, patients who underwent prior refractive surgery, keratoconus, limbal relaxing incisions for astigmatism management, realignment of a misplaced or rotated toric IOL, surgical induced astigmatism (SIA), formulae comparison, and other tools.</p><p><strong>Summary: </strong>As there are new online developments and technology is advancing rapidly, we hope that this review will assist ophthalmologists in becoming acquainted with a large variety of online tools.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71434827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-10-19DOI: 10.1097/ICU.0000000000001003
Ali Nowrouzi, Jorge L Alió
Purpose of review: This review aims to clarify the advantages and disadvantages of immediately sequential bilateral cataract surgery (ISBCS) based on recent studies, illustrate the safety of this approach, the cost-effectiveness, and present the importance of inclusion protocols for the best results.
Recent findings: In recent studies, the authors found no evidence of an increased risk of bilateral devastating complications such as endophthalmitis with ISBCS based on descriptive evidence compared to delayed sequential bilateral cataract surgery (DSBCS). Furthermore, recent studies on cost analyses showed that ISBCS resulted in fewer costs and significant cost savings to third-party payers, patients, and society compared to DSBCS.
Summary: The ISBCS surgical approach decreases hospital visits, reduces costs, and provides rapid visual rehabilitation and neuro adaptation. The risk of bilateral simultaneous complications is now recognized to be very rare with intracameral antibiotics and compliance with correct protocols. With new generations of optical biometry and lens calculation formulas, refractive surprises are occasional for normal eyes. However, refractive surprise is controversial, especially in the implantation of presbyopia correction intra-ocular lenses, which must be evaluated carefully in the ISBCS approach.
{"title":"Immediately sequential bilateral cataract surgery.","authors":"Ali Nowrouzi, Jorge L Alió","doi":"10.1097/ICU.0000000000001003","DOIUrl":"10.1097/ICU.0000000000001003","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to clarify the advantages and disadvantages of immediately sequential bilateral cataract surgery (ISBCS) based on recent studies, illustrate the safety of this approach, the cost-effectiveness, and present the importance of inclusion protocols for the best results.</p><p><strong>Recent findings: </strong>In recent studies, the authors found no evidence of an increased risk of bilateral devastating complications such as endophthalmitis with ISBCS based on descriptive evidence compared to delayed sequential bilateral cataract surgery (DSBCS). Furthermore, recent studies on cost analyses showed that ISBCS resulted in fewer costs and significant cost savings to third-party payers, patients, and society compared to DSBCS.</p><p><strong>Summary: </strong>The ISBCS surgical approach decreases hospital visits, reduces costs, and provides rapid visual rehabilitation and neuro adaptation. The risk of bilateral simultaneous complications is now recognized to be very rare with intracameral antibiotics and compliance with correct protocols. With new generations of optical biometry and lens calculation formulas, refractive surprises are occasional for normal eyes. However, refractive surprise is controversial, especially in the implantation of presbyopia correction intra-ocular lenses, which must be evaluated carefully in the ISBCS approach.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-10-26DOI: 10.1097/ICU.0000000000001009
Bryanna Lee, Natalie A Afshari, Peter X Shaw
Purpose of review: Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies.
Recent findings: Antioxidants serve as pivotal markers in cataract pathogenesis. GSH affects the central lens due to factors such as enzyme depletion and altered connexin expression, impairing GSH diffusion. Age-related oxidative stress may hinder GSH transport via connexin channels or an internal microcirculation system. N-acetylcysteine, a GSH precursor, shows promise in mitigating lens opacity when applied topically. Additionally, SOD, particularly SOD1, correlates with increased cataract development and gel formulations have exhibited protective effects against posterior subscapular cataracts. Lastly, markers of lipid peroxidation, MDA and 4-HNE, have been shown to reflect disease severity. Studies suggest a potential link between 4-HNE and connexin channel modification, possibly contributing to reduced GSH levels.
Summary: Oxidative stress is a significant contributor to cataract development, underscoring the importance of antioxidants in diagnosis and treatment. Notably, GSH depletion, SOD decline, and lipid peroxidation markers are pivotal factors in cataract pathogenesis, offering promising avenues for both diagnosis and therapeutic intervention.
{"title":"Oxidative stress and antioxidants in cataract development.","authors":"Bryanna Lee, Natalie A Afshari, Peter X Shaw","doi":"10.1097/ICU.0000000000001009","DOIUrl":"10.1097/ICU.0000000000001009","url":null,"abstract":"<p><strong>Purpose of review: </strong>Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies.</p><p><strong>Recent findings: </strong>Antioxidants serve as pivotal markers in cataract pathogenesis. GSH affects the central lens due to factors such as enzyme depletion and altered connexin expression, impairing GSH diffusion. Age-related oxidative stress may hinder GSH transport via connexin channels or an internal microcirculation system. N-acetylcysteine, a GSH precursor, shows promise in mitigating lens opacity when applied topically. Additionally, SOD, particularly SOD1, correlates with increased cataract development and gel formulations have exhibited protective effects against posterior subscapular cataracts. Lastly, markers of lipid peroxidation, MDA and 4-HNE, have been shown to reflect disease severity. Studies suggest a potential link between 4-HNE and connexin channel modification, possibly contributing to reduced GSH levels.</p><p><strong>Summary: </strong>Oxidative stress is a significant contributor to cataract development, underscoring the importance of antioxidants in diagnosis and treatment. Notably, GSH depletion, SOD decline, and lipid peroxidation markers are pivotal factors in cataract pathogenesis, offering promising avenues for both diagnosis and therapeutic intervention.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-10-16DOI: 10.1097/ICU.0000000000001007
Emilie Bergeron, Marc A Bouffard
Purpose of review: Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.
Recent findings: Current evidence highlights the need for prompt plasmapheresis as adjunct to intravenous methylprednisolone (IVMP) in patients with NMOSD-associated optic neuritis. Recent advances have included a proliferation of novel disease modifying therapies (DMTs) for long-term management of NMOSD and an understanding of how existing therapeutic options can be leveraged to optimally treat MOGAD.
Summary: In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are beneficial in the treatment of NMOSD-associated optic neuritis, with a shorter time-to-treatment associated with a higher likelihood of recovery. The natural history of untreated MOGAD-associated optic neuritis is unclear but treatment with IVMP is near-universal given phenotypic similarities with NMOSD. Long-term immunosuppressive therapy is warranted in patients with NMOSD as well as in patients with MOGAD with poor visual recovery or recurrent attacks.
{"title":"Evidence-based management of optic neuritis.","authors":"Emilie Bergeron, Marc A Bouffard","doi":"10.1097/ICU.0000000000001007","DOIUrl":"10.1097/ICU.0000000000001007","url":null,"abstract":"<p><strong>Purpose of review: </strong>Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.</p><p><strong>Recent findings: </strong>Current evidence highlights the need for prompt plasmapheresis as adjunct to intravenous methylprednisolone (IVMP) in patients with NMOSD-associated optic neuritis. Recent advances have included a proliferation of novel disease modifying therapies (DMTs) for long-term management of NMOSD and an understanding of how existing therapeutic options can be leveraged to optimally treat MOGAD.</p><p><strong>Summary: </strong>In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are beneficial in the treatment of NMOSD-associated optic neuritis, with a shorter time-to-treatment associated with a higher likelihood of recovery. The natural history of untreated MOGAD-associated optic neuritis is unclear but treatment with IVMP is near-universal given phenotypic similarities with NMOSD. Long-term immunosuppressive therapy is warranted in patients with NMOSD as well as in patients with MOGAD with poor visual recovery or recurrent attacks.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41240592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-21DOI: 10.1097/icu.0000000000001025
Teresa Borrás, Michelle Stepankoff, John Danias
To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.
介绍未来使用基因疗法治疗青光眼的最新进展。
{"title":"Genes as drugs for glaucoma: latest advances.","authors":"Teresa Borrás, Michelle Stepankoff, John Danias","doi":"10.1097/icu.0000000000001025","DOIUrl":"https://doi.org/10.1097/icu.0000000000001025","url":null,"abstract":"To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1097/icu.0000000000001020
Ariana M Levin, Arsham Sheybani
Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.
青光眼手术的快速创新扩大了房角、结膜下间隙和睫状上间隙的手术选择范围。
{"title":"Glaucoma surgical procedures under development.","authors":"Ariana M Levin, Arsham Sheybani","doi":"10.1097/icu.0000000000001020","DOIUrl":"https://doi.org/10.1097/icu.0000000000001020","url":null,"abstract":"Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01Epub Date: 2023-08-30DOI: 10.1097/ICU.0000000000001002
Sruti S Rachapudi, Noor A Laylani, Pamela A Davila-Siliezar, Andrew G Lee
Purpose of review: To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).
Recent findings: Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.
Summary: Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.
{"title":"Neuro-ophthalmic manifestations of Ehlers-Danlos syndrome.","authors":"Sruti S Rachapudi, Noor A Laylani, Pamela A Davila-Siliezar, Andrew G Lee","doi":"10.1097/ICU.0000000000001002","DOIUrl":"10.1097/ICU.0000000000001002","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).</p><p><strong>Recent findings: </strong>Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.</p><p><strong>Summary: </strong>Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1097/icu.0000000000000993
Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur
《当代眼科意见》创刊于1990年。它是一系列成功的评论期刊之一,其独特的格式旨在提供许多主要期刊中提出的文献的系统和批判性评估。眼科领域分为九个部分,每年审查一次。每个章节都有一个章节编辑,他是该领域的权威,负责确定当时最重要的主题。在这里,我们很高兴地介绍本刊的栏目编辑。Dean Cestari博士在康奈尔大学医学院纽约长老会医院完成了神经病学和眼科的住院医师培训,并在美国马萨诸塞州哈佛医学院马萨诸塞州眼耳医院接受了神经眼科的奖学金培训。他是美国大约10位获得美国眼科委员会和美国精神病学和神经病学委员会认证的医生之一。塞斯塔里博士成为了麻省理工学院的全职教员。眼耳医院是哈佛医学院的主要教学医院,于2006年成立,目前担任哈佛医学院眼科副教授。他非常热衷于医学教育,是马萨诸塞州眼耳医院临床奖学金项目的主任。作为一名临床医生兼科学家,他的工作重点是评估和治疗患有神经眼病的患者。他还积极参与甲状腺眼病伴斜视和复视的内科和外科治疗。他刚刚出版了一本外科教科书,名为《学习斜视手术,基于案例的方法》。他监督临床研究员,二年级住院医师和访问医学生,并进行成人斜视手术,并在手术室指导二年级住院医师。Cestari博士的转化研究重点是开发缺血性视神经病变和视网膜中央动脉闭塞的啮齿动物模型。一旦这项工作完成,他的团队将开始评估各种新型神经保护剂的安全性和有效性,这些保护剂可用于保护和恢复受血管闭塞影响的视力。此外,他正在与来自麻省理工学院和哈佛大学的工程师团队合作,设计并制造一种植入式装置,以恢复神经麻痹的失神经眼外肌的眼球运动。John Gonzales博士是美国加州大学旧金山分校Francis I. Proctor基金会的眼科副教授,专门研究葡萄膜炎和医用角膜。他得到了美国国立卫生研究院国家眼科研究所的早期职业奖的支持,利用Sjögren的国际临床合作联盟(sicca)队列研究Sjögren综合征中干燥性角膜结膜炎的频谱。Gonzales博士也在研究免疫正常个体巨细胞病毒前葡萄膜炎的治疗策略。Gonzales博士的兴趣也扩展到眼部肿瘤学,特别是原发性玻璃体视网膜淋巴瘤,他对临床特征如何与淋巴细胞增殖相关的突变以及对化疗药物的耐药性相关感兴趣。冈萨雷斯博士是《当代眼科学观点》栏目编辑,也是普罗克托基金会葡萄膜炎研究项目主任。
{"title":"Editorial introductions","authors":"","doi":"10.1097/icu.0000000000000993","DOIUrl":"https://doi.org/10.1097/icu.0000000000000993","url":null,"abstract":"Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136371349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01Epub Date: 2023-08-17DOI: 10.1097/ICU.0000000000000990
Marco Nassisi, Claudia Mainetti, Andrea Aretti, Andrea Sperti, Valeria Nicotra, Berardo Rinaldi, Federica Natacci, Maria Francesca Bedeschi, Francesco Viola
Purpose of review: The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.
Recent findings: Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.
Summary: Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.
{"title":"Ocular features in Williams-Beuren syndrome: a review of the literature.","authors":"Marco Nassisi, Claudia Mainetti, Andrea Aretti, Andrea Sperti, Valeria Nicotra, Berardo Rinaldi, Federica Natacci, Maria Francesca Bedeschi, Francesco Viola","doi":"10.1097/ICU.0000000000000990","DOIUrl":"10.1097/ICU.0000000000000990","url":null,"abstract":"<p><strong>Purpose of review: </strong>The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.</p><p><strong>Recent findings: </strong>Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.</p><p><strong>Summary: </strong>Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}